Application 208246
- Type
- NDA
- Sponsor
- PFIZER INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | XELJANZ XR | TOFACITINIB CITRATE | TABLET, EXTENDED RELEASE;ORAL | EQ 11MG BASE | Yes | Yes |
| 002 | XELJANZ XR | TOFACITINIB CITRATE | TABLET, EXTENDED RELEASE;ORAL | EQ 22MG BASE | Yes | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N208246-001 | XELJANZ XR | TOFACITINIB CITRATE | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 |
| N208246-002 | XELJANZ XR | TOFACITINIB CITRATE | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD, RS | 2019-12-12 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N208246-001 | AB |
| N208246-002 | AB |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N208246-001 | RE41783 | 2025-12-08 | Drug substance | 2016-03-18 | |
| N208246-001 | RE41783*PED | 2026-06-08 | Pediatric extension | ||
| N208246-001 | 11253523 | 2034-03-14 | U-3326 | 2022-03-23 | |
| N208246-001 | 11253523 | 2034-03-14 | U-3327 | 2022-03-23 | |
| N208246-001 | 11253523 | 2034-03-14 | U-3328 | 2022-03-23 | |
| N208246-001 | 11253523 | 2034-03-14 | U-3329 | 2022-03-23 | |
| N208246-001 | 9937181 | 2034-03-14 | Drug product | 2018-05-09 | |
| N208246-001 | 11253523*PED | 2034-09-14 | Pediatric extension | ||
| N208246-001 | 9937181*PED | 2034-09-14 | Pediatric extension | ||
| N208246-002 | RE41783 | 2025-12-08 | Drug substance | 2020-01-09 | |
| N208246-002 | RE41783*PED | 2026-06-08 | Pediatric extension | ||
| N208246-002 | 10639309 | 2034-03-14 | Drug product | 2020-06-03 | |
| N208246-002 | 11253523 | 2034-03-14 | U-3326 | 2022-03-23 | |
| N208246-002 | 11253523 | 2034-03-14 | U-3327 | 2022-03-23 | |
| N208246-002 | 11253523 | 2034-03-14 | U-3328 | 2022-03-23 | |
| N208246-002 | 11253523 | 2034-03-14 | U-3329 | 2022-03-23 | |
| N208246-002 | 10639309*PED | 2034-09-14 | Pediatric extension | ||
| N208246-002 | 11253523*PED | 2034-09-14 | Pediatric extension |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD, RS | 2019-12-12 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD, RS | 2019-12-12 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | AB | RLD | 2016-02-23 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N208246-002 | XELJANZ XR | EQ 22MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2019-12-12 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD, RS | 2016-02-23 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N208246-001 | XELJANZ XR | EQ 11MG BASE | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-02-23 | bb7c543d1eb4… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N208246-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208246-001 | AB | 1 | 31067a03dcf5… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208246-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208246-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208246-001 | AB | 1 | 03ed91905a0d… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N208246-001 | AB | 1 | 1e350fbaab3a… |
| 2021-12-28 21:50 UTC | 2021-12 | N208246-001 | AB | 1 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | N208246-002 | AB | 1 | 782e0a99824c… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N208246-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N208246-002 | AB | 1 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | RE41783 | 2025-12-08 | Drug substance | 2016-03-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | RE41783*PED | 2026-06-08 | Pediatric extension | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | 11253523 | 2034-03-14 | U-3326 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | 11253523 | 2034-03-14 | U-3327 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | 11253523 | 2034-03-14 | U-3328 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | 11253523 | 2034-03-14 | U-3329 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | 9937181 | 2034-03-14 | Drug product | 2018-05-09 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | 11253523*PED | 2034-09-14 | Pediatric extension | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N208246-001 | 9937181*PED | 2034-09-14 | Pediatric extension | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | RE41783 | 2025-12-08 | Drug substance | 2020-01-09 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | RE41783*PED | 2026-06-08 | Pediatric extension | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | 10639309 | 2034-03-14 | Drug product | 2020-06-03 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | 11253523 | 2034-03-14 | U-3326 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | 11253523 | 2034-03-14 | U-3327 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | 11253523 | 2034-03-14 | U-3328 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | 11253523 | 2034-03-14 | U-3329 | 2022-03-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | 10639309*PED | 2034-09-14 | Pediatric extension | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N208246-002 | 11253523*PED | 2034-09-14 | Pediatric extension | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | RE41783 | 2025-12-08 | Drug substance | 2016-03-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | RE41783*PED | 2026-06-08 | Pediatric extension | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | 11253523 | 2034-03-14 | U-3326 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | 11253523 | 2034-03-14 | U-3327 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | 11253523 | 2034-03-14 | U-3328 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | 11253523 | 2034-03-14 | U-3329 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | 9937181 | 2034-03-14 | Drug product | 2018-05-09 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | 11253523*PED | 2034-09-14 | Pediatric extension | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N208246-001 | 9937181*PED | 2034-09-14 | Pediatric extension | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | RE41783 | 2025-12-08 | Drug substance | 2020-01-09 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | RE41783*PED | 2026-06-08 | Pediatric extension | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | 10639309 | 2034-03-14 | Drug product | 2020-06-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | 11253523 | 2034-03-14 | U-3326 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | 11253523 | 2034-03-14 | U-3327 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | 11253523 | 2034-03-14 | U-3328 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | 11253523 | 2034-03-14 | U-3329 | 2022-03-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | 10639309*PED | 2034-09-14 | Pediatric extension | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N208246-002 | 11253523*PED | 2034-09-14 | Pediatric extension | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N208246-001 | RE41783 | 2025-12-08 | Drug substance | 2016-03-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208246-001 | RE41783*PED | 2026-06-08 | Pediatric extension | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N208246-001 | 11253523 | 2034-03-14 | U-3326 | 2022-03-23 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208246-001 | 11253523 | 2034-03-14 | U-3327 | 2022-03-23 | 011fe1cb6892… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208246-001 | I-879 | 2024-12-14 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208246-001 | I-879 | 2024-12-14 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N208246-001 | I-879 | 2024-12-14 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N208246-001 | I-879 | 2024-12-14 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N208246-001 | I-879 | 2024-12-14 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N208246-001 | I-879 | 2024-12-14 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N208246-001 | I-879 | 2024-12-14 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N208246-001 | I-879 | 2024-12-14 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N208246-001 | I-879 | 2024-12-14 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208246-001 | I-879 | 2024-12-14 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N208246-001 | I-879 | 2024-12-14 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N208246-001 | I-879 | 2024-12-14 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N208246-001 | I-761 | 2020-12-14 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N208246-001 | I-879 | 2024-12-14 | bb7c543d1eb4… |
| 2020-12-22 03:56 UTC | 2020-12 | N208246-001 | I-761 | 2020-12-14 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N208246-001 | I-761 | 2020-12-14 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N208246-001 | I-761 | 2020-12-14 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N208246-001 | I-761 | 2020-12-14 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N208246-001 | I-761 | 2020-12-14 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N208246-001 | I-879 | 2024-12-14 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N208246-001 | I-879 | 2024-12-14 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N208246-001 | I-879 | 2024-12-14 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N208246-001 | I-879 | 2024-12-14 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N208246-001 | I-879 | 2024-12-14 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N208246-001 | I-879 | 2024-12-14 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N208246-001 | I-879 | 2024-12-14 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N208246-001 | I-879 | 2024-12-14 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N208246-001 | I-879 | 2024-12-14 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N208246-001 | I-879 | 2024-12-14 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N208246-001 | I-879 | 2024-12-14 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | N208246-001 | I-879 | 2024-12-14 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N208246-001 | I-879 | 2024-12-14 | cb3db0bc1861… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0501 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-0502 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 63539-501 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-501 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-501 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-501 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-501 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-501 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-502 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-502 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-502 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-502 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 85322 | SUPPL | 2026-03-11 |
| 85302 | SUPPL | 2026-03-09 |
| 85348 | SUPPL | 2026-03-06 |
| 81359 | SUPPL | 2025-02-25 |
| 81333 | SUPPL | 2025-02-24 |
| 79782 | SUPPL | 2024-09-30 |
| 79770 | SUPPL | 2024-09-27 |
| 78510 | SUPPL | 2024-05-20 |
| 78480 | SUPPL | 2024-05-15 |
| 69589 | SUPPL | 2021-12-16 |
| 69565 | SUPPL | 2021-12-15 |
| 69564 | SUPPL | 2021-12-15 |
| 69481 | SUPPL | 2021-12-06 |
| 69469 | SUPPL | 2021-12-03 |
| 69468 | SUPPL | 2021-12-03 |
| 61271 | SUPPL | 2019-12-13 |
| 61270 | SUPPL | 2019-12-13 |
| 61265 | SUPPL | 2019-12-13 |
| 59898 | SUPPL | 2019-09-12 |
| 59902 | SUPPL | 2019-08-30 |
| 59493 | SUPPL | 2019-07-29 |
| 59470 | SUPPL | 2019-07-26 |
| 56072 | SUPPL | 2018-10-23 |
| 56039 | SUPPL | 2018-10-19 |
| 55260 | SUPPL | 2018-08-21 |
| 55217 | SUPPL | 2018-08-20 |
| 50709 | SUPPL | 2017-12-15 |
| 50701 | SUPPL | 2017-12-15 |
| 49532 | SUPPL | 2017-08-24 |
| 49529 | SUPPL | 2017-08-24 |
| 48822 | ORIG | 2017-06-26 |
| 40628 | ORIG | 2016-02-26 |
| 32900 | ORIG | 2016-02-25 |